Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® ...

SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH ® (palopegteriparatide) by the Therapeutic Goods ...

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the ...

It was a rough night for Patrick Mahomes at the 2025 Super Bowl. He threw a bunch of interceptions, got sacked a lot, and he ...

Despite the trial's halt, Septerna remains committed to developing an oral small molecule PTH1R agonist for hypoparathyroidism and plans to select a next-generation candidate from its portfolio of ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

Septerna Inc.’s stock plunged as much as 68% throughout the day Feb. 18 on news that the company was stopping a phase I trial of SEP-786 in healthy volunteers following two severe events of elevated ...

The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis conducted by Future Market Insights. In 2022, the market was valued at USD 777.4 ...

Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic ...